Kyverna Therapeutics Inc. is a patient-centered clinical-stage biopharmaceutical company focused on developing cell therapies for patients suffering from autoimmune diseases. The company's lead product candidate includes KYV-101. Kyverna Therapeutics Inc. is based in EMERYVILLE, Calif.
| Revenue (Most Recent Fiscal Year) | $7.03M |
| Net Income (Most Recent Fiscal Year) | $-127.48M |
| PE Ratio (Current Year Earnings Estimate) | -- |
| PE Ratio (Trailing 12 Months) | -- |
| PEG Ratio (Long Term Growth Estimate) | -- |
| Price to Sales Ratio (Trailing 12 Months) | -- |
| Price to Book Ratio (Most Recent Quarterly Book Value per Share) | 0.86 |
| Price to Cash Ratio (Most Recent Annual Cash Flow per Share) | -- |
| Pre-Tax Margin (Trailing 12 Months) | -- |
| Net Margin (Trailing 12 Months) | -- |
| Return on Equity (Trailing 12 Months) | -64.98% |
| Return on Assets (Trailing 12 Months) | -56.17% |
| Current Ratio (Most Recent Fiscal Quarter) | 5.39 |
| Quick Ratio (Most Recent Fiscal Quarter) | 5.39 |
| Debt to Common Equity (Most Recent Fiscal Quarter) | 0.00 |
| Inventory Turnover (Trailing 12 Months) | -- |
| Book Value per Share (Most Recent Fiscal Quarter) | $4.26 |
| Earnings per Share (Most Recent Fiscal Quarter) | $-0.97 |
| Earnings per Share (Most Recent Fiscal Year) | $-3.33 |
| Diluted Earnings per Share (Trailing 12 Months) | $-3.68 |
| Exchange | NASDAQ |
| Sector | Healthcare |
| Industry | Biotechnology |
| Common Shares Outstanding | 43.25M |
| Free Float | 33.73M |
| Market Capitalization | $159.58M |
| Average Volume (Last 20 Days) | 0.28M |
| Beta (Past 60 Months) | 3.05 |
| Percentage Held By Insiders (Latest Annual Proxy Report) | 22.00% |
| Percentage Held By Institutions (Latest 13F Reports) | 18.08% |
| Annual Dividend (Based on Last Quarter) | $0.00 |
| Dividend Yield (Based on Last Quarter) | 0.00% |